tangeretin has been researched along with Ventricular Dysfunction, Left in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bunbupha, S; Kukongviriyapan, U; Maneesai, P; Pakdeechote, P; Rattanakanokchai, S; Tong-Un, T; Wunpathe, C | 1 |
1 other study(ies) available for tangeretin and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Tangeretin mitigates l-NAME-induced ventricular dysfunction and remodeling through the AT
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Flavones; Male; NG-Nitroarginine Methyl Ester; Rats; Rats, Sprague-Dawley; Signal Transduction; Ventricular Dysfunction, Left | 2020 |